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Introduction
During the last ten years important achievements have 
been made throughout the world in the fight against in-
fectious diseases, particularly those preventable by vac-
cination. the combined efforts of researchers, industry 
and health workers have made it possible to fully exploit 
the potential of the new vaccines, using them in the most 
rational way possible on the basis of the latest epidemio-
logical data and objectives to be achieved.
in italy, in common with other countries, precise objec-
tives have been established in the fight against vaccine 
preventable disease, appropriate operating strategies 
have been developed and a vaccination schedule has 
been defined. this latter harmonises mandatory and rec-
ommended vaccinations and indicates the chronological 
sequence in which they should be performed. the vac-
cination calendar is an indispensable tool for achieving 
the objectives of the various immunisations uniformly 
throughout italy.
it is vitally important that this vaccination schedule is 
updated on the basis of the latest scientific knowledge, 
the changed epidemiological situation of the various 
infectious diseases, possible changes in organisational 
requirements and, above all, the availability of new 
products [1, 2].
the success achieved so far against diseases for which 
mandatory vaccination exists (diphtheria, tetanus, polio 
and hepatitis b) is strictly related to the high levels of 
vaccination coverage reached and maintained nation-
wide. For recommended vaccinations, the situation is 
more diversified, although data from the latest iCONa 
survey show that in the case of antigens included in the 
hexavalent vaccines, high levels of vaccination cover-
age have been obtained (pertussis and Haemophilus 
influenzae type b). However, for measles, mumps and 
rubella, although a significant increase in vaccination 
coverage, the level critical for eliminating the diseases 
has not yet been reached [3, 4].
Over and above achievement of the established vac-
cination coverage objectives, the action taken over the 
years has influenced the epidemiology of the various 
diseases with a reduction in morbidity and generally a 
lower spreading of the corresponding infectious agents. 
in some cases, there are also problems associated with 
the length of protection provided by the vaccines and 
the consequent need not just to optimise vaccinations in 
newborns but also to plan booster vaccinations. these 
latter are essential to avoid the creation of clusters of 
newly susceptible subjects among adolescents and 
adults, previously successfully vaccinated, due both to 
the decay of immunity and the reduced spreading of 
microrganisms [5].
the 2005-2007 italian National Vaccination Plan 
(iNVP) has underlined the importance of reaching and 
maintaining high vaccination coverage rates in child-
hood; besides, the iNVP emphasizes that indications 
exist for booster vaccinations for tetanus, diphtheria, 
pertussis and polio, beginning from pre-school age and 
every ten years in adult life, as indicated by the current 
italian national vaccination schedule [6].
the practical indications are backed by Presidential De-
cree no. 464 of 7 November 2001 [7], which, modifying 
the provisions of the fourth clause of article 2 of Presi-
dential Decree no. 1301 of 7 September 1965, states:
• booster vaccinations with administration of tetanus 
anatoxin, possibly in combination with diphtheria 
anatoxin and/or other antigens, should be given at 
10-year intervals;
• in infants and children who begin anti-tetanus vacci-
nation before the age of 7 (aged 6), the first booster 
should be given, with administration of tetanus ana-
toxin possibly in combination with diphtheria ana-
toxin and/or other antigens, 4-5 years after the last 
dose of the primary vaccination series. Subsequent 
boosters should be given at 10-year intervals.
The epidemiological update
TeTanus
as it is well known, tetanus is important not for its inci-
dence (quite low), but for its lethality which approaches 
about 50% of the cases.
Mandatory vaccination against tetanus was introduced 
in italy in 1968, with administration of three doses 
during the first year of life (3, 5 and 11-12 months) fol-
lowed by a booster at 5-6 years old.
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the available epidemiological data show that since 
mandatory vaccination was introduced, the italian teta-
nus epidemiology has progressively improved and 
the trend of notifications has dropped dramatically, 
levelling out at about 100 cases/year [8]. the majority 
of cases are clustered in the older age groups and in 
particular in women more than 64 years old. this last 
figure is related to the fewer opportunities for receiving 
boosters among the female population (e.g. missing the 
previous mandatory service in the army). Noteworthy, 
stratifying national tetanus notifications by vaccination 
status, it emerges clearly that the majority of cases are 
related to incomplete series of vaccinations or no vac-
cination [9].
the existence of cohorts of susceptible subjects is con-
firmed by seroepidemiological studies clearly indicating 
that, while vaccination coverage among infants remains 
consistently high, the percentage of susceptible or less 
than optimally protected subjects rises with age, related 
to the absence of booster vaccinations. the need for 
catch-up of subjects above the age of mandatory vac-
cination and of regulations on revaccination and booster 
doses has recently (as explained above) been sanctioned 
by Presidential Decree no. 464 of 7 November 2001 [7].
DiphTheria
Diphtheria can cause serious respiratory and heart 
problems and in the most severe cases prove fatal [10]. 
From an epidemiological point of view, this infectious 
disease is worldwide endemic. However, following the 
introduction of effective vaccination programmes, it is 
now rare in Western Europe and the industrialised coun-
tries. the epidemics, which occurred in the 90’s in the 
former Russia, showed that even severe outbreaks can 
reoccur if adequate levels of vaccination coverage are 
not maintained [11].
in italy, the mandatory vaccination, introduced in 1939, 
involves administration of three doses during the first 
year of life (at 3, 5 and 11-12 months) and one booster 
dose at 5-6 years. achievement and maintenance of high 
levels of vaccination coverage have enabled signifi-
cant results to be obtained with a dramatic drop in the 
number of notifications and no case reported for many 
years [10]. this drop can without doubt be interpreted 
as a success for the vaccination strategy adopted. How-
ever, as underlined for tetanus, the seroepidemiological 
data indicate a progressive accumulation of susceptible 
or less than optimally protected subjects in the older 
age groups [12, 13]. these studies confirm the changes 
induced by the extensive vaccination campaigns on the 
seroepidemiological trend for diphtheria. as a matter of 
fact, before vaccination, seroprevalence increased with 
aging as a consequence of infection; in adolescents and 
young adults, a plateau was reached as a consequence 
of persisting contact with C. diphtheriae in the environ-
ment. after the introduction of vaccination, extensive 
immunization has enabled high rates of seroprevalence 
to be obtained by the age of two. However, in the 
absence of natural boosters, this tends to drop progres-
sively with age [14-17]. Just as described for tetanus, to 
maintain adequate levels of diphtheria antibodies, it is 
therefore advisable to administer regular boosters (every 
10 years) with adult td vaccine as sanctioned by Presi-
dential Decree no. 464 of 7 November 2001 [7].
perTussis
Without vaccination, pertussis is a typical childhood dis-
ease with a considerable impact, particularly on infants, 
involving frequent and serious complications including 
pneumonia, convulsions and encephalopathy with hos-
pitalisation and deaths. in the world, it is estimated that 
there are about 20-40 million cases/year of the disease, 
with about 200,000-400,000 deaths [18, 19].
Pertussis vaccination was recommended by the italian 
Ministry of Health in 1962. However, the vaccination 
coverage has been low for years, particularly in the 
Southern Regions of italy. until 1991, vaccination cov-
erage did not exceed 40% and therefore control of the 
disease was inadequate [20].
in 1994, the introduction of acellular pertussis vaccines, 
considerably less reactogenic than whole cell ones, 
encouraged the spread of vaccination, helped by its 
inclusion in combined vaccines for administration to in-
fants according to a three-dose schedule (3, 5 and 11-12 
months) with a booster at 5-6 years. the percentage of 
vaccinations in infants aged between 12 and 24 months 
thus increased rapidly, reaching 88% in 1998 and 95% 
in 2003 [21].
However, humoral and cellular immunity tends to drop 
after about three years and to disappear about 10-12 
years after vaccination [22, 23]. thus, the lowering im-
munity implies a growing number of adolescents and 
adults susceptible to pertussis and a consequently higher 
incidence in subjects in these age groups.
Comparison of the epidemiological data from countries 
with low and high vaccination coverage shows that in 
areas with low vaccination coverage during childhood, 
the incidence of pertussis is high in children and low in 
adolescents and adults. in countries with a high level of 
vaccination coverage in childhood, incidence is, on the 
other hand, high in adolescents and adults [24].
all this is paradigmatic of the different immunological 
pressure on circulation of B. pertussis. in the case of no 
or low vaccination coverage, frequent natural boosters 
occur and therefore naturally acquired immunity may 
persist in adolescents and adults. in the case of high 
vaccination coverage, natural boosters  are consider-
ably lower, a decay of immunity occurs in adolescents/
adults, and the disease is more frequent in infants (as 
they are not yet completely vaccinated), adolescents and 
adults [25].
this fact is particularly important if the different clinical 
profile of pertussis in relation to the patient’s age is con-
sidered; noteworthy, in adolescents and adults, pertussis 
is often mild, with aspecific symptoms, and therefore 
not diagnosed. as the illness is often not recognised in 
adolescents/adults, the latest therefore become a signifi-
cant source of infection for infants [26].
in italy, the increase in vaccination coverage in child-
hood is related to an increase of the mean age of in-
booster vaccinations against diphtheria, tetanus, pertussis and polio
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fection. During recent years, there has been a greater 
morbidity in older children, adolescents and adults. 
Recent epidemiological surveys carried out in italy have 
shown an increase in cases in the 5-9 and 10-14 year 
old age groups, a marked reduction of incidence and an 
increase in the mean age of cases [21]. More recently, 
a multicenter study confirmed that the epidemiology 
of pertussis in italy is changing in the same way as in 
other countries with a high level of vaccination cover-
age [27].
as adolescents/adults may infect infants who have not 
yet been vaccinated, spreading of Bordetella pertussis 
beyond the age of childhood is not just an obstacle to its 
elimination but also a limit to controlling the disease as 
it contributes to transmitting pertussis to the age groups 
at the greatest risk of complications.
For these reasons, the opportunity of booster vaccina-
tions should be carefully evaluated. this active prophy-
laxis is today facilitated by the fact that latest generation 
acellular vaccines can be used on subjects over seven 
years old. Further, new vaccines are available with acel-
lular pertussis component and reduced antigen content 
(including for tetanus and diphtheria), suitable for use 
in adolescents and adults. if the target is to avoid an 
increase of the mean age of pertussis infection, action 
must be taken on adolescents and adults by means of a 
booster dose with a reduced antigen vaccine [28].
poliomyeliTis
Vaccination against polio has enabled extraordinary 
targets to be achieved [29, 30]. in italy, vaccination 
with live and attenuated vaccine (OPV) began with the 
mass vaccination of 1964, followed by vaccination of 
all infants with three doses administered during the first 
year of life and a booster dose in the third year of life. 
More recently, the strategy against this important infec-
tious disease has been modified, first in 1999 when the 
vaccination schedule exclusively based on oral polio 
vaccine (OPV) was replaced by a sequential schedule 
with administration of two doses of inactivated polio 
vaccine (iPV) followed by two doses of OPV and sub-
sequently in June 2002, following WHO certification of 
the eradication of polio from the European Region, with 
adoption of a schedule based on administration of iPV 
only. the modifications have not changed the level of 
vaccination coverage which has remained high through-
out italy. From an epidemiological point of view, circu-
lation of wild poliovirus is currently confined to certain 
countries in africa and the indian subcontinent. this 
represents an excellent precondition for eradicating this 
disease. However, as there are still focuses of infection, 
there is a remote possibility of the disease being reintro-
duced into safe territories [31].
the certification obtained at national level in italy in 
June 2002 was based on the established absence of 
clinical cases and circulation of wild poliovirus both at 
human and environmental level. the documented pres-
ence of vaccine poliovirus in the faeces of some subjects 
and in sewage can be correlated to administration of the 
vaccine. the sustained circulation of vaccine strains 
between humans has not been demonstrated. Given this 
epidemiological situation, the immunological pressure 
exerted by vaccination has eliminated or greatly reduced 
the possibility of natural boosters and therefore the level 
of neutralising antibodies in the population has progres-
sively dropped. the exclusive use of inactivated iPV 
vaccine today also implies a level of mucosal protec-
tion considerably lower than in subjects who received 
the complete series or at least two doses of OPV. it is 
therefore considered that booster vaccination, already 
adopted in some countries [32], may enable this nega-
tive aspect in cohorts exclusively immunised with iPV 
to be overcome. With these motivations and the aim of 
guaranteeing a booster vaccination at a suitable distance 
from the primary series, in the 2005-2007 iNVP it was 
decided to shift the fourth dose of iPV from the 3rd 
year of life to the 5th-6th year coinciding with the DtaP 
booster.
Booster vaccinations
the considerable amount of scientific data collected 
in the recent years shows that the distinction between 
vaccination schedules for children, adolescents, adults 
and the elderly is outdated and we now need to think in 
terms of a single vaccination schedule covering the vari-
ous phases of life. it is equally obvious that adoption of 
well-organised vaccination schemes with thorough cov-
erage of the population has enabled fundamental results 
to be obtained in the fight against many infectious dis-
eases, substantially modifying the epidemiology of the 
diseases and circulation of the etiological agents [33].
there is now the need to consolidate the successes 
obtained, evaluate the consequences of the immunologi-
cal pressure exerted by vaccination on the pathogenic 
agents and guarantee continuity of vaccination. booster 
vaccinations provide a way of resolving this last point, 
important in guaranteeing long-term protection of suc-
cessfully vaccinated subjects, but who may in some 
cases be exposed to new risks of acquiring the infection 
and/or disease as a result of the decay of immune pro-
tection provided by vaccination, the lower possibility 
of natural boosters or the reintroduction of a pathogen 
already eliminated in italy from areas where it is en-
demic.
the 2005-2007 italian National Vaccination Plan (iNVP) 
clearly recognizes the need to plan boosters to avoid cre-
ating cohorts of partially or totally susceptible subjects, 
identifying two timeframes of intervention: 5-6 years 
(for tetanus, diphtheria, pertussis and polio) and 11-15 
years of age (for tetanus, diphtheria and pertussis).
New vaccines available
the possibility of high compliance with booster vacci-
nations is strictly related to a series of factors, particular 
important among which are tolerability, efficacy and 
number of injections.
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this last point has always been critical and the availabil-
ity of combined vaccines has without doubt represented 
an excellent opportunity as, for the same level of safety 
and efficacy, they guarantee fewer injections and ac-
cesses to services [34].
With reference to the indications in the 2005-2007 
iNVP, the availability of combined vaccines for tetanus, 
diphtheria, pertussis and polio boosters is therefore an 
important resource. GlaxoSmithKline Spa has devel-
oped two products derived from the infanrix family of 
vaccines, namely Polioinfanrix and Polioboostrix for 
booster immunisation against tetanus, diphtheria, per-
tussis and polio, differing in antigen content and indica-
tions for use (tab. i).
Polioinfanrix has a paediatric antigen content and is in-
dicated for subjects from 16 months to 13 years of age 
inclusive; Polioboostrix has a reduced antigen content 
(of the tetanus, diphtheria and pertussis components) 
and is indicated for subjects over four years of age. 
both vaccines contain three Bordetella pertussis antigen 
components: pertussis toxoid (Pt), filamentous hae-
magglutinin (FHa) and pertactin (PRN). the presence 
of the three antigen components, (mainly PRN), confers 
them higher efficacy with respect to the other commer-
cially available products with two antigen components 
(Pt and FHa) [35].
Polioinfanrix can be administered in a single 0.5 ml 
dose by intramuscular injection to subjects who have 
previously received acellular or whole cell pertussis 
vaccines and live and attenuated oral polio vaccines 
or injectable inactivated ones [36, 37]. Clinical studies 
performed on more than 2000 subjects (15-26 months 
and 10-14 years of age), previously vaccinated with 
three or four doses of combined diphtheria, tetanus 
and pertussis (whole cell or acellular) vaccine and who 
have completed the primary series, have indicated an 
excellent safety profile. as expected, booster doses with 
DtaP vaccines can be more reactogenic in children pre-
viously vaccinated with products containing acellular 
pertussis components. However, the adverse reactions 
noted during the studies generally occur within 48 hours 
from immunisation, are light/moderate and resolve 
spontaneously without sequelae. immunogenicity is 
also excellent. the immune responses after the booster 
with Polioinfanrix, assessed in more than 900 subjects, 
were irrespective of the number of doses and type of 
vaccines administered previously. Ninety nine per cent 
of the immunised subjects had protective levels of anti-
bodies against diphtheria, tetanus and the three types of 
poliovirus, irrespective of the age of the subjects (15-26 
months, 4-7 years or 10-13 years). although there is no 
serologic correlate of protection for pertussis antigens, 
concentrations of Pt, FHa and PRN antibodies after 
administration of Polioinfanrix were always higher than 
those registered after primary vaccination with the com-
bined paediatric pertussis vaccine, indicating a probable 
high level of protective efficacy against pertussis.
Polioboostrix is administered in a single dose (0.5 
ml intramuscular) for the booster vaccination against 
diphtheria, tetanus, pertussis and polio in subjects aged 
four years or more. it is not indicated for primary im-
munisation. the principal characteristic of the product 
is the low antigen content of the diphtheria, tetanus and 
pertussis components. it can be used to treat wounds at 
risk of tetanus infection in subjects who received the 
primary vaccination series with tetanus toxoid and for 
whom a diphtheria, pertussis and polio booster is indi-
cated [38-42]. Evaluated by administering the vaccine to 
more than 1500 subjects in various age groups (4-8, 10-
14 and more than 15 years) who had previously received 
four doses of DtaP or DtwP (4-8 or 10-14 years) or 
at least one primary series of Dt with a mean interval 
of 16.4 years since the last immunisation, the safety 
profile of Polioboostrix was found to be excellent. the 
most frequent adverse events were slight/moderate and 
local (pain, redness and swelling in the inoculation site) 
reported in 36.4-66.9% of subjects, generally occurring 
during the 48 hours following vaccination and clearing 
up spontaneously without sequelae. Similarly to safety, 
the immunogenicity profile was also evaluated in clini-
cal studies carried out on subjects of different ages and 
with different vaccination histories. the seroprotection 
level and vaccine response to all antigens one month 
after the booster dose were similar to those observed 
in controlled studies performed with already registered 
vaccines (tab. ii). as far as the pertussis components 
Tab. I. Qualitative and quantitative composition (1 dose: 0.5 ml).
Ag PolioInfanrix PolioBoostrix
diphtheria toxoid not less than 30 iu not less than 2 iu (2.5lf)
tetanus toxoid not less than 40 iu not less than 20 iu (5lf)
pertussis toxoid (pt) 25 μg 8 μg
Filamentous haemagglutinin (Fha) 25 μg 8 μg
pertactin (prn) 25 μg 8 μg
type 1 inactivated polio (mahoney strain) 40 d 40 d
type 2 inactivated polio (meF-1 strain) 8 d 8 d
type 3 inactivated polio (saukett strain) 32 d 32 d
aluminium hydroxide hydrate 0.5 mg al3 + 0.3 mg al3 +
aluminium phosphate - 0.2 mg al3 +
booster vaccinations against diphtheria, tetanus, pertussis and polio
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are concerned, the antibody concentrations achieved 
were found to be similar to or even higher than those ob-
served during an efficacy study performed on household 
contacts with the paediatric acellular combined vaccine, 
suggesting that Polioboostrix is expected to provide a 
high level of protection against pertussis.
Intervention options
Combined vaccines for tetanus, diphtheria, acellular per-
tussis and polio have been conceived and developed to 
provide a vaccine suitable for adolescents and/or adults. 
by guaranteeing high tolerability and immunogenicity, 
they enable booster vaccinations to be extended from 
tetanus alone to also include diphtheria, pertussis and 
polio [34]. the vaccines with a reduced dtap antigen 
content today available in Europe, the uSa, Canada, 
australia and many other countries are recommended for 
adolescents, selected categories of health workers and peo-
ple in close contact with infants and children [43-46]. Epi-
demiological data on polio indicate the need to reinforce 
the immune response in populations vaccinated with 
iPV and many countries have planned specific action 
with booster vaccinations [32]. in italy, the 2005-2007 
iNVP stresses the need “to maintain over time the high 
level of immune protection provided by vaccination 
during childhood … Currently the problem of boosters 
exists not just for tetanus, but also for diphtheria and 
pertussis, but there are indications that polio could also 
be included on this list”.
the two new vaccines mentioned about fall within this 
context. in particular, the Polioinfanrix vaccine has an 
antigen content similar to that of paediatric vaccines and 
is indicated for boosters in subjects aged from 16 months 
Tab. II. immunogenicity of polioboostrix vaccine.
Ag Response Subjects 10-93 years
n = 690
(% of vaccinated subjects)
Subjects 4-8 years
n = 779
(% of vaccinated subjects)
diphtheria ≥ 0.1 iu/ml* 83.5-100 100
≥ 0.016 iu/ml^ 87.7-100 na°
tetanus ≥ 0.1 iu/ml 99.6-100 99.9
pertussis pt ** 94.2-97.1 97.8
pertussis Fha ** 96.9-97.2 90.1
pertussis prn ** 96.6-99.3 96.5
type 1 polio ≥ 8 99.6-100 100
type 2 polio ≥ 8 99.6-100 100
type 3 polio ≥ 8 99.1-100 100
* elisa assay; ^ vero-cell in vitro neutralisation assay; ° not available; ** concentration > 5 eu/ml in subjects seronegative before 
the booster or at least double the antibody concentrations in subjects seropositive before the booster.
Tab. III. range of incidence of specifically monitored events observed in clinical trials on adults, who had received the reduced antigen 
vaccine [dtap; boostrixtm], the adult tetanus and diphtheria vaccine [td] or the reduced acellular pertussis antigen vaccine [ap], as a booster 
(from di pasquale et al., 2005 [50], mod.).
dTpa % Td % ap %
Pain
all 72.6-88.5 82.7-85.2 56.4-71.9
class 3* 0.5-0.9 0.0 3.6-3.7
Redness
≥ all sizes 32.0-33.3 34.7-38.9 12.5-20.0
≥ 50 mm 2.3-2.7 3.7-11.1 0.0
Swelling
≥ all sizes 20.8-28.1 26.5-29.6 10.4-10.9
≥ 50 mm 2.3-2.7 3.7-7.4 0.0
Fever** (≥ 37.5°C)
≥ all 5.2-18.5 9.2-33.3 4.2-12.7
≥  39.0°c 0.0-0.4 0.0 0.0
* class 3 defined as pain preventing normal everyday activities; ** axillary temperature
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to 13 years, while Polioboostrix has a reduced tetanus, 
diphtheria and pertussis antigen content and is indicated 
for boosters in subjects since four years of age.
With reference to the above, clearly expressed on the 
Summary of Product Characteristics (SPC), the booster 
vaccinations provided for by current italian legislation 
at the age of 5-6 years could be performed using either 
Polioinfanrix or Polioboostrix.
the 2005-2007 iNVP does not support the use of dtpa 
vaccine formulation in the pre-school children. Such 
assumption is based on the results of one immunogenic-
ity study carried out in italy, where the anti-diphtheria 
adult formulation vaccines generated a geometric mean 
antibody concentrations lower than those achieved with 
the paediatric formulation one (14.1 vs. 7.7 iu/ml, in Dt 
and dt group, respectively; p < 0.05) [47]. On this basis, 
the authors speculate that the immune protection is then 
expected not to last for a sufficient period of time before 
the subsequent booster is given. it is worth noting that 
the immunogenicity and reactogenicity results obtained 
with Dt or dt vaccine in six year old children were 
not similar in the two groups of subjects, as redness 
and swelling in the inoculation site were significantly 
more frequent in the Dt group. Nevertheless, the au-
thors’ conclusion was that the better immunogenicity 
and comparable reactogenicity of the Dt vaccine sug-
gested it would be more appropriate than dt vaccines 
for boosters in pre-school age children, in particular as 
boosters were not routinely given to adolescents and 
adults [47].
Tab. IV. range of incidence of specifically monitored events observed in clinical trials on adolescents, who had received the reduced antigen 
vaccine [dtap; boostrixtm], the adult tetanus and diphtheria vaccine [td] or the reduced acellular pertussis antigen vaccine [ap], as a booster 
(from di pasquale et al., 2005 [50], mod.).
dTpa % Td % ap %
Pain
≥ all 79.0-80.4 78.3-83.3 67.8-68.9
≥ class 3* 0.0 0.0 0.0
Redness 
≥ any 17.4-33.0 32.6-53.3 8.9-15.3
≥ 50 mm 0.0 4.3 0.0
Redness
≥ all sizes 19.6-35.0 37.0-46.7 15.3-15.6
≥ 50 mm 0.0 4.3 0.0
Fever** (≥ 37.5 °C)
≥ all 2.2-8.9 8.3-8.7 5.1-6.7
≥ 39.0 °c 0.0-0.2 0.0 0.0
* class 3 defined as pain preventing normal everyday activities; ** axillary temperature
Tab. V. range of incidence of specifically monitored events observed in clinical trials on pre-school children, who had received the reduced anti-
gen vaccine [dtap; boostrixtm] or the adult tetanus and diphtheria vaccine [td], as a booster, compared with paediatric combined whole cell vaccine 
for diphtheria-tetanus and pertussis (dtwp) or acellular diphtheria-tetanus and pertussis vaccine (dtap) (from di pasquale et al., 2005 [50], mod.).
dTpa % Td % DTwP % DTaP %
Pain
≥ all 41.8 51.7 67.3 63.3
≥ class 3* 0.6 2.3 1.5 2.2
Redness
≥ all sizes 23.6 36.8 33.9 48.9
≥ 50 mm 1.2 17.2 3.6 23.3
Swelling
≥ all sizes 21.2 34.5 44.2 43.3
≥ 50 mm 0.6 13.8 4.8 15.6
Fever** (≥ 37.5 °C)
≥ all 13.9 32.2 30.9 22.2
≥ 39.0 °c 1.8 4.6 4.8 4.4
* class 3 defined as pain preventing normal everyday activities; ** axillary temperature
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it should be noted that the above study made no com-
parison with the dtap vaccine commercially available 
in italy today (boostrix) which has a diphtheria toxoid 
content of 2.5Lf, higher than in the dt vaccines assessed 
in the above study.
More recently, a series of articles were published on 
the excellent safety and immunogenicity profile of 
boostrix [48-51] (tabs. iii-V). in 2004, Cheuvart et al. 
to assess the impact of the two vaccines over the years 
applied a mathematical model to the results obtained on 
sera collected from 4-6 years old children and until 3.5 
years after administration of DtaP or dtap vaccines. 
the model predicted that ten years after vaccination 
(the timeframe indicated at international level as the 
correct moment to administer the booster) the number 
of subjects protected against diphtheria did not differ 
significantly between the two groups of vaccinated 
subjects (98.6% vs. 99.6%, with dtap and DtaP, re-
spectively) (tab. Vi). according to the authors, the dif-
ferences in GMt noted one month after administration 
of a booster dose at 4-6 years of age with DtaP or dtap 
did not exert any clinical relevance in the long-term (10 
years) [52].
the combined DtaP-iPV and dtap-iPV vaccines there-
fore represent an important resource to guarantee vacci-
nation continuity. Considering the unquestionable need 
to increase booster vaccinations after pre-school age 
and that health workers and users are always concerned 
about the safety and reactogenicity of vaccines, the 
availability of products with a reduced antigen content 
and guaranteeing excellent immunogenicity and safety 
and lower reactogenicity than vaccines with a paediatric 
antigen dosage will help achieve and maintain high lev-
els of coverage from as early as pre-school age.
Tab. VI. predicted anti-diphtheria antibody gmc values (extended 
elisa measurememt) 10 years after booster vaccination of chil-
dren aged 4-6 years (from cheuvart et al., 2004 [52], mod.).
Vaccine GMC (ELISAext)
at year 10
% ≥ 0.0149 IU/ml
at year 10
S.D. 0.4
dtpa 0.112 98.6
dtpa 0.170 99.6
td 0.141 99.3
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